Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nymox raises $15 million in equity financing
The financing gives the company the right to place common stock to the investors at a 3% discount to the market price of the company’s stock. Paul Averback,
The financing gives the company the right to place common stock to the investors at a 3% discount to the market price of the company’s stock. Paul Averback,
This expanded program is funded by and coordinated with Meda, BDSI’s US and European commercial partner for Bema Fentanyl. Under this new program, BDSI and Meda plan to
Glipizide or Metformin HCl is indicated as initial therapy, as an adjunct to diet and exercise, to improve glycemic control in patients with type 2 diabetes whose hyperglycemia
Health Canada’s approval of Eloxatin was based on clinical data collected over several years. The MOSAIC trial compared the efficacy and evaluated the safety of Eloxatin in combination
The approved patent protects the composition and method behind the company’s oral probiotic product formulation Kibow Biotics, which may significantly reduce concentrations of several nitrogenous waste metabolites that
Under the agreement, VWR will distribute Axela’s proprietary dotLab system and reagents across North America. This arrangement significantly expands VWR’s instrumentation offerings in the protein research sector. Axela’s
This patented technology relates to surgical devices, such as percutaneously insertable catheters and cannulas that are used to access the circulatory system. These devices can be used in
Kamada has already obtained orphan drug designation from both the FDA and the EMEA for aerosolized Alpha-1 Antitrypsin (AAT) for the treatment of congenital emphysema and cystic fibrosis.
The companies will work collaboratively to provide seamless training, installation and customer support services. John Kershaw, president of Sysmex America, said: “We believe our agreement with healthcare veteran
The agreement includes an option to Merck for exclusive worldwide licenses for such peptides – on a peptide by peptide basis – covering the development and commercialization of